Latest Financial Results
16 April 2025 – 1 mins read
LinkedIn
Facebook
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
13 February 2025 – 1 mins read
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
24 April 2024 – 1 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 29 Financial Results
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
26 October 2023
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.
27 July 2023
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…
27 April 2023
LinkedIn
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023
09 February 2023
LinkedIn
Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
Your dedicated contacts
-
Khalid Deojee
Senior Manager, Investor Relations
